Corbus Pharmaceuticals Holdings, INC Form 4 insider transactions

Sean Moran, CFO of Corbus Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

CEO Yuval Cohen reports the acquisition of restricted stock units and stock options in Corbus Pharmaceuticals.

Cormorant Asset Management, LP, along with related entities and Bihua Chen, reported purchasing additional shares of Corbus Pharmaceuticals Holdings, Inc. on September 20, 2024, increasing their beneficial ownership.

Director Winston Kung reports acquisition of 5,566 shares of common stock and stock options in Corbus Pharmaceuticals Holdings, Inc.

Sean Moran, CFO of Corbus Pharmaceuticals, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Corbus Pharmaceuticals' CEO, Yuval Cohen, exercised stock options and sold shares between June 14 and June 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Alan Holmer, a director of Corbus Pharmaceuticals Holdings, Inc., reported the exercise of stock options and holdings of restricted stock units (RSUs) in a recent SEC filing.

Director John Jenkins received 2,783 restricted stock units (RSUs) in Corbus Pharmaceuticals Holdings, Inc., which will vest in one year.

Director Avery Catlin reports the grant of restricted stock units (RSUs) in Corbus Pharmaceuticals.

Director Peter Salzmann of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Director Rachelle Jacques received 2,783 restricted stock units (RSUs) of Corbus Pharmaceuticals Holdings, Inc. on May 30, 2024, which will vest in one year.

Director Yong Ben of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Director Alan Holmer received 2,783 restricted stock units in Corbus Pharmaceuticals Holdings, Inc. on May 30, 2024, which will vest in one year.

Director Anne Altmeyer of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Director Peter Salzmann acquired 2,783 stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Director John Kenneth Jenkins acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Director Rachelle Suzanne Jacques acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Director Alan Holmer acquired 2,783 stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024, according to a Form 4 filing.

Director Avery W. Catlin acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024, as part of the company's 2024 Equity Compensation Plan.

Director Yong Ben received a stock option award for 2,783 shares of Corbus Pharmaceuticals common stock on May 16, 2024.

Director Anne Altmeyer acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Sean F. Moran, CFO of Corbus Pharmaceuticals, exercised stock options and holds a significant number of unvested restricted stock units.

Cormorant Asset Management, LP, along with related entities and Bihua Chen, reports the acquisition of additional shares of Corbus Pharmaceuticals Holdings, Inc. common stock through a series of open market transactions.

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals, was granted 50,000 restricted stock units and stock options for 50,000 shares on February 27, 2024.